VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+4.9%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$265M
AUM Growth
+$37.5M
(+17%)
Cap. Flow
+$31.7M
Cap. Flow
% of AUM
11.98%
Top 10 Holdings %
Top 10 Hldgs %
9.25%
Holding
421
New
24
Increased
206
Reduced
145
Closed
45
Top Buys
| 1 |
DT Midstream
DTM
|
$1.86M |
| 2 |
ScottsMiracle-Gro
SMG
|
$878K |
| 3 |
Valero Energy
VLO
|
$790K |
| 4 |
FMC
FMC
|
$775K |
| 5 |
Delek US
DK
|
$761K |
Top Sells
| 1 |
COR
Coresite Realty Corporation
COR
|
$1.67M |
| 2 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$601K |
| 3 |
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
|
$551K |
| 4 |
Travere Therapeutics
TVTX
|
$479K |
| 5 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
$448K |
Sector Composition
| 1 | Real Estate | 22.39% |
| 2 | Healthcare | 18.38% |
| 3 | Energy | 15.88% |
| 4 | Materials | 14.07% |
| 5 | Utilities | 13.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AMTI
276
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
| $172K | 0.07% |
12,313
+7,981
| +184% | +$111K |
|
277
Allogene Therapeutics
ALLO
$246M
| $171K | 0.06% |
11,487
+3,108
| +37% | +$46.3K |
|
278
Cue Biopharma
CUE
$60.3M
| $171K | 0.06% |
15,125
-511
| -3% | -$5.78K |
|
279
Kodiak Sciences
KOD
$452M
| $171K | 0.06% |
2,013
-485
| -19% | -$41.2K |
|
|
KRON
280
DELISTED
Kronos Bio
KRON
| $171K | 0.06% |
12,548
+4,422
| +54% | +$60.3K |
|
|
AMRS
281
DELISTED
Amyris Inc.
AMRS
| $171K | 0.06% |
31,527
+17,947
| +132% | +$97.3K |
|
|
AGEN
282
Agenus
AGEN
$137M
| $170K | 0.06% |
2,691
+584
| +28% | +$36.9K |
|
|
IGMS
283
DELISTED
IGM Biosciences
IGMS
| $170K | 0.06% |
5,787
+3,574
| +162% | +$105K |
|
284
Seres Therapeutics
MCRB
$165M
| $170K | 0.06% |
1,019
+504
| +98% | +$84.1K |
|
285
Olema Pharmaceuticals
OLMA
$436M
| $170K | 0.06% |
18,150
+11,036
| +155% | +$103K |
|
286
Cartesian Therapeutics
RNAC
$260M
| $170K | 0.06% |
1,738
+324
| +23% | +$31.7K |
|
287
Revolution Medicines
RVMD
$7.28B
| $170K | 0.06% |
6,746
+596
| +10% | +$15K |
|
|
AFMD
288
DELISTED
Affimed
AFMD
| $169K | 0.06% |
3,059
+517
| +20% | +$28.6K |
|
289
Aligos Therapeutics
ALGS
$74.7M
| $169K | 0.06% |
568
+295
| +108% | +$87.8K |
|
290
Celldex Therapeutics
CLDX
$1.51B
| $169K | 0.06% |
4,382
-3,483
| -44% | -$134K |
|
291
Arcus Biosciences
RCUS
$1.23B
| $169K | 0.06% |
4,179
-4,485
| -52% | -$181K |
|
|
VXRT
292
DELISTED
Vaxart
VXRT
| $169K | 0.06% |
26,883
+2,552
| +10% | +$16K |
|
293
Zymeworks
ZYME
$1.07B
| $169K | 0.06% |
10,324
+4,727
| +84% | +$77.4K |
|
|
DICE
294
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $169K | 0.06% |
+6,683
| New | +$169K |
|
|
FMTX
295
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $169K | 0.06% |
11,902
+3,143
| +36% | +$44.6K |
|
296
Intellia Therapeutics
NTLA
$1.25B
| $168K | 0.06% |
1,425
-994
| -41% | -$117K |
|
297
Sutro Biopharma
STRO
$86.5M
| $168K | 0.06% |
11,305
+238
| +2% | +$3.54K |
|
|
CNTA
298
Centessa Pharmaceuticals
CNTA
$2.12B
| $167K | 0.06% |
+14,798
| New | +$167K |
|
299
CRISPR Therapeutics
CRSP
$4.8B
| $167K | 0.06% |
2,203
+559
| +34% | +$42.4K |
|
300
Regenxbio
RGNX
$476M
| $167K | 0.06% |
5,112
-548
| -10% | -$17.9K |
|